C1-C2 point monitoring of low-dose cyclosporin A given as a single daily dose in children with steroid-dependent relapsing nephrotic syndrome

2005 ◽  
Vol 64 (10) ◽  
pp. 258-263 ◽  
Author(s):  
T. Nakahata ◽  
H. Tanaka ◽  
K. Tsugawa ◽  
M. Kudo ◽  
K. Suzuki ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Cyclosporin A ◽  
Low Dose ◽  
Single Daily Dose ◽  
Steroid Dependent ◽  
Daily Dose

Long-term low-dose cyclosporin A in steroid dependent nephrotic syndrome of childhood

1992 ◽  
Vol 151 (10) ◽  
pp. 775-778 ◽  
Author(s):  
T. J. Neuhaus ◽  
H. R. Burger ◽  
M. Klingler ◽  
A. Fanconi ◽  
E. P. Leumann
Keyword(s):  
Nephrotic Syndrome ◽  
Cyclosporin A ◽  
Low Dose ◽  
Steroid Dependent ◽  
Steroid Dependent Nephrotic Syndrome

Linear Growth of Low-Dose Cyclosporin A Therapy in Children with Steroid-Dependent Nephrotic Syndrome

Nephron ◽  
2001 ◽  
Vol 87 (3) ◽  
pp. 293-294 ◽  
Author(s):  
Kenichi Kano ◽  
Kiyoshi Nishikura ◽  
Megumi Hoshi ◽  
Yumi Yamada ◽  
Osamu Arisaka
Keyword(s):  
Nephrotic Syndrome ◽  
Cyclosporin A ◽  
Low Dose ◽  
Linear Growth ◽  
Steroid Dependent ◽  
Steroid Dependent Nephrotic Syndrome

scholarly journals Clinical Response and Pattern of B cell Suppression with Single Low Dose Rituximab in Nephrology

Kidney360 ◽  
2020 ◽  
Vol 1 (5) ◽  
pp. 359-367
Author(s):  
Jacob George ◽  
Sunu Alex ◽  
E.T. Arun Thomas ◽  
Noble Gracious ◽  
Nalanda S. Vineetha ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
B Cells ◽  
B Cell ◽  
Clinical Response ◽  
Low Dose ◽  
Clinical Status ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cell Percentage ◽  
Steroid Dependent

BackgroundThere is no consensus regarding dose and frequency of rituximab in nephrology with extrapolation of doses used in treating lymphoproliferative disorders. There are no guidelines on targeting initial and subsequent doses on the basis of CD19+ B cells.MethodsInitially, 100 mg rituximab was given to 42 adults with steroid-dependent nephrotic syndrome (SDNS) and frequently relapsing nephrotic syndrome (FRNS), idiopathic membranous nephropathy (MN), and high-immunologic-risk kidney transplantation. Absolute and percentage levels of CD19 B cells and clinical status were assessed at baseline, days 30, 90, and 180, and at 1 year. Subsequent doses of rituximab were on the basis of CD19 B cell reconstitution and clinical response.ResultsCD19 B cell percentage decreased from 16.3 ± 7.6 to 0.3 ± 0.3 (P≤0.001), 1.9 ± 1.7 (P≤0.001), and 4.0 ± 4.5 (P=0.005) by 30, 90, and 180 days, respectively. Suppression of CD19 B cell count below 1% at days 30, 90, and 180 was seen in 40 of 42 (95.2%), 18 of 42 (42.9%), and 7 of 42 (16.7%) patients, respectively. Of 30 with SDNS and FRNS followed up for 1 year, 29 (96.7%) went into remission at day 30. Remission was sustained in 23 (76.6%) at day 180 and 21 (70%) at 1 year. There was a significant decrease (P<0.001) in the dose of steroids needed to maintain remission at 180 days after rituximab (0.27 ± 0.02 mg/kg to 0.02 ± 0.00 mg/kg). CD19 B cell percentage at 90 days correlated with relapse (P=0.001; odds ratio 1.42; 95% confidence interval, 1.25 to 2.57). Eighteen (60%) required an additional dose. Of five with MN, four achieved remission by 6 months, which was sustained in three by 1 year. Of the seven kidney transplant recipients, two had antibody-mediated rejections, although CD19 B cells were suppressed even at 1 year.ConclusionsLow-dose rituximab induces sustained depletion of CD19 B cells for up to 90 days. Its role in preventing relapses in SDNS, FRNS, MN, and rejection needs further study.

Single daily dose of cyclosporine in patients with primary glomerulonephritis and nephrotic syndrome

2007 ◽  
Vol 67 (05) ◽  
pp. 285-292 ◽  
Author(s):  
F.M. Rasche ◽  
F. Keller ◽  
G. Kunze ◽  
B. Boesler ◽  
D. Czock
Keyword(s):  
Nephrotic Syndrome ◽  
Single Daily Dose ◽  
Primary Glomerulonephritis ◽  
Daily Dose

The effect of alternate-day low dose prednisolone on bone age in children with steroid dependent nephrotic syndrome

1997 ◽  
Vol 29 (3) ◽  
pp. 357-361 ◽  
Author(s):  
Z. Bircan ◽  
M. Soran ◽  
I. Yildirim ◽  
M. Doĝan ◽  
A. Şahin ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Low Dose ◽  
Bone Age ◽  
Steroid Dependent ◽  
Steroid Dependent Nephrotic Syndrome

Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study

2020 ◽  
Vol 35 (8) ◽  
pp. 1437-1444
Author(s):  
Pietro Ravani ◽  
Francesca Lugani ◽  
Isabella Pisani ◽  
Monica Bodria ◽  
Giorgio Piaggio ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Low Dose ◽  
Randomized Controlled Study ◽  
Controlled Study ◽  
Randomized Controlled ◽  
Steroid Dependent ◽  
Steroid Dependent Nephrotic Syndrome

scholarly journals Efficacy of Semiannual Single Fixed Low-Dose Rituximab Therapy in Steroid-Dependent Minimal Change Nephrotic Syndrome: A Case Series

2018 ◽  
Vol 8 (3) ◽  
pp. 230-237 ◽  
Author(s):  
Ryosuke Usui ◽  
Yohei Tsuchiya ◽  
Kosaku Nitta ◽  
Minako Koike
Keyword(s):  
Nephrotic Syndrome ◽  
Low Dose ◽  
Chemotherapy Regimen ◽  
Case Series ◽  
Minimal Change Nephrotic Syndrome ◽  
Minimal Change ◽  
Cell Hyperplasia ◽  
Conventional Dose ◽  
Steroid Dependent ◽  
Refractory Nephrotic Syndrome

The frequency of using rituximab to treat refractory nephrotic syndrome has recently been increasing, and the conventional dose of rituximab used to treat it, 375 mg/m2 body surface area once weekly for 4 weeks, has been modelled on the chemotherapy regimen for B-cell non-Hodgkin’s lymphoma. The dose and intervals of rituximab in refractory nephrotic syndrome remain controversial. Clear lymphoma cell hyperplasia is seen in lymphoma patients, but not in nephrotic syndrome patients. Since we thought that it might be possible to reduce the dose of rituximab if only used for the purpose of depleting CD20-positive B cells in nephrotic patients’ peripheral blood, we tried semiannually with a single fixed rituximab dose of 100 mg/body, and a complete remission was attained in 3 cases without treatment with prednisolone or cyclosporine. Our report strongly suggests considering appropriate dose and interval of rituximab therapy in the treatment of steroid-dependent nephrotic syndrome.

Skeletal effects of low-dose cyclosporin A therapy in children with nephrotic syndrome

2000 ◽  
Vol 4 (4) ◽  
pp. 313-317
Author(s):  
K. Kano ◽  
K. Kyo ◽  
K. Nishikura ◽  
M. Hoshi ◽  
S. Ito ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Cyclosporin A ◽  
Low Dose ◽  
Skeletal Effects

scholarly journals Cyclosporin-A Treatment in Steroid Nonresponsive Nephrotic Syndrome

2018 ◽  
Vol 34 (1-2) ◽  
pp. 1-7
Author(s):  
IGN Wila Wirya ◽  
Taralan Tambunan ◽  
Husein Alatan
Keyword(s):  
Nephrotic Syndrome ◽  
Cyclosporin A ◽  
Partial Remission ◽  
Good Alternative ◽  
Major Advance ◽  
Gingival Hyperplasia ◽  
Steroid Dependent ◽  
Function Impairment ◽  
Frequent Relapsers ◽  
Total Remission

Fifteen patients with steroid nonresponsive nephrotic syndrome (NS) aged 4-16 years received oral cyclosporin-A (CyA) for 12 weeks. Nine of the patients were boys. Out of the 15 patients, 7 were frequent relapsers, 3 were steroid dependents, 4 were steroid resistants and one with toxic steroid. After 12 weeks of CyA treatment;, 6 patients showed complete remission, 7 showed partial remission, and 2 patients did not respond at all. Side effects observed were slight renal function impairment, gingival hyperplasia, and a hump on the breast; all disappeared gradually after stopping CyA. Patients with total remission experienced relapse 2 to 12 months after discontinuation of CyA, while patients with partial remission experienced relapse 2 weeks to 3 months after CyA was discontinued A tentative conclusion can be drawn that CyA is a good alternative in the treatment of idiopathic NS, especially in steroid dependent patients who are at risk of developing steroid toxicity. CyA represent a major advance in the treatment selected SN patients who have failed with the conventional modes of therapy.

The effect of alternate-day low-dose prednisolone on bone age in children with steroid-dependent nephrotic syndrome

1996 ◽  
Vol 10 (3) ◽  
pp. 397-398
Author(s):  
Zel�l Bircan ◽  
Mustafa Soran ◽  
Idris Yildirim ◽  
Meral Dogan ◽  
Arif Sahin ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Low Dose ◽  
Bone Age ◽  
Steroid Dependent ◽  
Steroid Dependent Nephrotic Syndrome
Sign in / Sign up

Export Citation Format

Share Document